Trial Profile
Randomized Phase II Trial of Intralesional Lymphokine Activated Killer Cells or Polifeprosan 20 With Carmustine Implant (Gliadel Wafer) as Consolidation Therapy After Primary Treatment of Newly Diagnosed Resectable Glioblastoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma
- Focus Therapeutic Use
- Sponsors Caladrius Biosciences
- 09 May 2019 Status changed from discontinued to withdrawn prior to enrolment.
- 03 Jun 2009 New trial record.